![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GSK Seeks EU Approval for Pulmonary Disease Triple Combo T
GSK Seeks EU Approval for Pulmonary Disease Triple Combo T
December 12, 2016
GSK has filed for marketing approval with the EMA for its triple combination therapy to treat chronic obstructive pulmonary disease.
The submission is based on results from a Phase 3 trial of the triple combo therapy. That study found that the candidate significantly reduced the worsening of COPD symptoms, like shortness of breath and phlegm accumulation, compared to standard once-daily treatments.
Last month, GSK submitted an NDA for its COPD candidate that combines the company’s Relvar/Breo Ellipta and Anoro Ellipta.
Upcoming Events
-
21Oct